New treatment options in intermittent claudication: The US experience

International Journal of Clinical Practice, Supplement

Volumn , Issue 119, 2001, Pages 20-27

  Hiatt, W R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ARGININE; BASIC FIBROBLAST GROWTH FACTOR; BERAPROST; CILOSTAZOL; NAFTIDROFURYL; PENTOXIFYLLINE; PROPIONYLCARNITINE; PROSTAGLANDIN E1; VASCULOTROPIN;

CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL TRIAL; DRUG EFFICACY; EXERCISE; FLUSHING; HEADACHE; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS;

ARGININE; CARNITINE; ENDOTHELIAL GROWTH FACTORS; EXERCISE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; MULTICENTER STUDIES; NAFRONYL; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS; TETRAZOLES; UNITED STATES;

EID: 0035049983     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Diagnostic methods for peripheral arterial disease in the San Luis Valley Diabetes Study
2. The prevalence of peripheral arterial disease in a defined population
3. Current and future drug therapies for claudication
4. Exercise rehabilitation for patients with peripheral arterial disease
5. Perspectives on the assessment and management of intermittent claudication
6. Update on some epidemiologic features of intermittent claudication: The Framingham Study
7. The peripheral vascular consequences of smoking
8. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis
9. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)
10. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
11. Secondary prevention of vascular disease by prolonged antiplatelet treatment
12. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study
13. A randomised, blinded, trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE)
14. Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: Status in 1997
15. Exercise therapy for claudication
16. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis
17. Effect of daily muscular exercise in patients with intermittent claudication
18. Intermittent claudication - Surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency
19. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: Alone or combined?
20. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response
21. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
22. Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials
23. Does oxpentifylline ('Trental') have a place in the treatment of intermittent claudication?
24. Placebo-controlled double-blind study with pentoxifylline of walking performance in patients with intermittent claudication
25. Another look at the pentoxifylline efficacy data for intermittent claudication
26. Intravenous treatment of chronic peripheral occlusive arterial disease: A double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline
27. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease
28. Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial
29. Cilostazol or pentoxifylline for claudication?
30. The effect of withdrawal of drugs treating intermittent claudication
31. A comparison of cilostazol and pentoxifylline for treating intermittent claudication
32. Cilostazol: A novel treatment option in intermittent claudication
33. Intermittent claudication: A double-blind crossover trial of pentoxifylline
34. Pentoxifylline therapy for chronic claudication: Are patients dependent on therapy?
35. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial
36. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
37. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication
38. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease
39. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease
40. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication
41. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease
42. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs
43. Carnitine metabolism during exercise in patients with peripheral vascular disease
44. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: A double-blind, cross-over study
45. Superiority of L-propionylcarnitine versus L-carnitine in improving walking capacity in patients with peripheral vascular disease: An acute, intravenous, double-blind, cross-over study
46. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study
47. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: A multicentre controlled study vs. placebo
48. European multicenter study on propionyl-L-carnitine in intermittent claudication
49. Effect of propionyl-L-carnitine on quality of life in intermittent claudication
50. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostagtandin E1
51. 1 or intravenous pentoxifylline during training
52. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication
53. A dose-effect study of beraprost sodium in intermittent claudication
54. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model
55. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia
56. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia